Zobrazeno 1 - 10
of 1 138
pro vyhledávání: '"J. Rybak"'
Autor:
Kaylee E. Caniff, Chloe Judd, Kristen Lucas, Sandra Goro, Caroline Orzol, Mirna Eshaya, Mohammed Al Musawa, Michael P. Veve, Michael J. Rybak
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 12, Pp 2649-2662 (2024)
Abstract Introduction Infective endocarditis (IE) due to methicillin-resistant Staphylococcus aureus (MRSA) is characterized by frequent treatment failure to first-line agents and high mortality, necessitating use of alternative management strategies
Externí odkaz:
https://doaj.org/article/2489e482a39c4d1799baa5ba7fb520b1
Autor:
Ashlan J. Kunz Coyne, Mirna Eshaya, Callan Bleick, Samantha Vader, Biswajit Biswas, Melanie Wilson, Michael V. Deschenes, Jose Alexander, Susan M. Lehman, Michael J. Rybak
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 10 (2024)
ABSTRACT In the era of antimicrobial resistance, phage-antibiotic combinations offer a promising therapeutic option, yet research on their synergy and antagonism is limited. This study aims to assess these interactions, focusing on protein synthesis
Externí odkaz:
https://doaj.org/article/b17c23568e9b4a98a2dd3df4ef75edc7
Autor:
Nicholas Rebold, Sara Alosaimy, Jeffrey C. Pearson, Brandon Dionne, Ahmad Taqi, Abdalhamid Lagnf, Kristen Lucas, Mark Biagi, Nicholas Lombardo, Joshua Eudy, Daniel T. Anderson, Monica V. Mahoney, Wesley D. Kufel, Joseph A. D’Antonio, Bruce M. Jones, Jeremy J. Frens, Tyler Baumeister, Matthew Geriak, George Sakoulas, Dimitrios Farmakiotis, Dino Delaportas, Jeremy Larew, Michael P. Veve, Michael J. Rybak
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 3, Pp 565-579 (2024)
Abstract Introduction Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers to discharge or who require prolonged parenteral antibiotic cour
Externí odkaz:
https://doaj.org/article/329fe8cb8de8423a9b5e528288ac79f6
Autor:
Ashlan J. Kunz Coyne, Kyle Stamper, Callan Bleick, Razieh Kebriaei, Susan M. Lehman, Michael J. Rybak
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 4 (2024)
ABSTRACTMethicillin-resistant Staphylococcus aureus (MRSA) causes biofilm-related medical device infections. Phage-antibiotic combinations offer potential therapy due to proven in vitro antibiofilm efficacy. We evaluated phage-antibiotic synergy agai
Externí odkaz:
https://doaj.org/article/439d3dcf62f84a31af6b4e37edbf0bdc
Autor:
Razieh Kebriaei, Jacinda C. Abdul-Mutakabbir, Kyle C. Stamper, Katherine L. Lev, Michael J. Rybak
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 10, Pp 2485-2494 (2023)
Abstract Introduction Daptomycin (DAP) has proven to be a viable alternative amid vancomycin resistance; however, the use of DAP post vancomycin treatment has led to the development of DAP non-susceptible (DNS) strains. Dalbavancin (DAL), a novel sin
Externí odkaz:
https://doaj.org/article/abbed413ff56495ba1b00743046d207d
Autor:
Amer El Ghali, Ashlan J. Kunz Coyne, Kristen Lucas, Molly Tieman, Xhilda Xhemali, Suet-ping Lau, Gabriela Iturralde, Andrew Purdy, Dana J. Holger, Esther Garcia, Michael P. Veve, Michael J. Rybak
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 2 (2024)
ABSTRACTMulti-drug resistant gram-negative bacteria present a significant global health threat. Cefiderocol (CFDC), a siderophore cephalosporin, has shown potential in combating this threat, but with the currently available data, its role in therapy
Externí odkaz:
https://doaj.org/article/dd8cbdc6b5e441c988efa50e6056b091
Autor:
Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Abdalhamid M. Lagnf, Taylor Morrisette, Kyle C. Molina, Alaina DeKerlegand, Melanie Rae Schrack, S. Lena Kang-Birken, Athena L.V. Hobbs, Jazmin Agee, Nicholson B. Perkins, Mark Biagi, Michael Pierce, James Truong, Justin Andrade, Jeannette Bouchard, Tristan Gore, Madeline A. King, Benjamin M. Pullinger, Kimberly C. Claeys, Shelbye Herbin, Reese Cosimi, Serina Tart, Michael P. Veve, Bruce M. Jones, Leonor M. Rojas, Amy K. Feehan, Marco R. Scipione, Jing J. Zhao, Paige Witucki, Michael J. Rybak
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 1 (2024)
ABSTRACT Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical and microbiological outcomes in addition to associated adverse effects of eravacycline used in U.S. ho
Externí odkaz:
https://doaj.org/article/c7670c6ad2ab4a279e5ee3917f0e0369
Autor:
Marisa Zenaide Ribeiro Gomes, Elisangela Martins de Lima, Caio Augusto Martins Aires, Polyana Silva Pereira, Juwon Yim, Fernando Henrique Silva, Caio Augusto Santos Rodrigues, Thamirys Rachel Tavares e Oliveira, Priscila Pinho da Silva, Cristiane Monteiro Eller, Claudio Marcos Rocha de Souza, Michael J. Rybak, Rodolpho Mattos Albano, Antonio Basílio de Miranda, Edson Machado, Marcos Catanho, Nucleus of Hospital Research (NPH) study collaborators
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-19 (2023)
Abstract Polymyxin-carbapenem-resistant Klebsiella pneumoniae (PCR-Kp) with pan (PDR)- or extensively drug-resistant phenotypes has been increasingly described worldwide. Here, we report a PCR-Kp outbreak causing untreatable infections descriptively
Externí odkaz:
https://doaj.org/article/84f85823158f4344bb2b057a4a64a8b7
Autor:
Ashlan J. Kunz Coyne, Kyle Stamper, Amer El Ghali, Razieh Kebriaei, Biswajit Biswas, Melanie Wilson, Michael V. Deschenes, Truc T. Tran, Cesar A. Arias, Michael J. Rybak
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 4 (2023)
ABSTRACT Enterococcus faecium is a difficult-to-treat pathogen with emerging resistance to most clinically available antibiotics. Daptomycin (DAP) is the standard of care, but even high DAP doses (12 mg/kg body weight/day) failed to eradicate some va
Externí odkaz:
https://doaj.org/article/8dfc54dd9eb448adbe3bb0d313b8d146
Autor:
Jacinda C. Abdul-Mutakabbir, Nana Sakyi Opoku, Karen K. Tan, Peter Jorth, Victor Nizet, Hansel M. Fletcher, Keith S. Kaye, Michael J. Rybak
Publikováno v:
Antibiotics, Vol 13, Iss 1, p 47 (2024)
With the increase in carbapenem-resistant A. baumannii (CRAB) infections, there has been a resurgence in the use of polymyxins, specifically colistin (COL). Since the reintroduction of COL-based regimens in treating CRAB infections, several COL-resis
Externí odkaz:
https://doaj.org/article/5ae6b67e3cb44ec99d3e65c898a57272